Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Brian Shuster Joins MPM BioImpact as Entrepreneur Partner
MPM BioImpact appoints Brian Shuster as Entrepreneur Partner to bolster its initiatives in innovative therapies. Shuster's extensive experience in biotechnology and corporate development is expected to enhance MPM's Empresario Partner model and support its mission of advancing healthcare solutions.
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designation
Johnson & Johnson received FDA Fast Track designation for posdinemab, targeting early Alzheimer's disease by slowing tau pathology spread. JNJ-2056, another therapy, aims to delay AD onset in preclinical populations. Both therapies reflect J&J's commitment to addressing Alzheimer's unmet needs through innovative treatments.
Ferring's gut microbiome drug clears phase 3 trial in C. diff
Ferring Pharma's phase 3 trial of RBX2660, a microbiome therapy for Clostridioides difficile infection, shows preliminary positive efficacy. The therapy, derived from healthy gut bacteria, aims to repopulate the GI tract and out-compete C. diff. Ferring plans to discuss regulatory filing with the FDA, highlighting the therapy's potential to reduce recurrent infections without antibiotics.
FDA Approval and Biosimilars: Amgen's Pavblu™, BKEMV, and Wezlana™
The article highlights FDA approvals of biosimilars, including Amgen’s Pavblu™, BKEMV, and Wezlana™, alongside updates on biosimilar developments and litigation trends. It also covers significant biosimilar market developments and legal rulings affecting biosimilar competition and patent disputes.
FDA Approval, Amgen, Prescription Drugs: Insights into Biosimilars and Market Trends
The article highlights recent FDA approvals of biosimilars, including Amgen’s Pavblu™, BKEMV, Wezlana™, and RIABNI™, alongside updates on biosimilar developments and litigation trends. It also mentions the FDA’s advisory panel recommendations and the ongoing evolution of the U.S. biosimilar market.
Formycon and Fresenius Kabi Canada receive Health Canada Approval for Otulfi® (ustekinumab)
Health Canada approved Otulfi® (ustekinumab), a biosimilar to Stelara®, for treating serious inflammatory diseases via subcutaneous and intravenous formulations. This follows approvals by the FDA and European Commission. Formycon AG and Fresenius Kabi aim to enhance patient access to essential medicines and reduce healthcare costs, with commercialization in Canada set as per a March 2024 agreement.
Formycon and Fresenius Kabi Canada receive Health Canada Approval for FYB202/Otulfi®
Health Canada approved Formycon AG and Fresenius Kabi's FYB202/Otulfi®, a biosimilar to Stelara®, for treating several conditions. This follows U.S. FDA and European Commission approvals. The approval, based on comprehensive data, supports Formycon's mission to enhance access to affordable medicines and reduce healthcare costs.
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Oncocyte Corp. appoints Dr. Paul Billings as Consulting Chief Medical Officer. With over 40 years in genomics and precision medicine, Dr. Billings will support strategic and clinical goals, leveraging his experience in diagnostics and patient care to enhance Oncocyte's offerings in molecular diagnostics and organ transplant monitoring.
Johnson & Johnson's Alzheimer's Therapies Receive FDA Fast Track Designation
Johnson & Johnson received FDA Fast Track designation for posdinemab and JNJ-2056, targeting Alzheimer's. Posdinemab is in Phase 2b for early Alzheimer's; JNJ-2056 targets preclinical Alzheimer's. These therapies aim to address unmet needs, with potential to expedite treatment availability, despite risks in development and approval.
Johnson & Johnson's Alzheimer's Therapies Receive FDA Fast Track Designations
Johnson & Johnson received FDA Fast Track designation for posdinemab and JNJ-2056, targeting Alzheimer's disease. Posdinemab is in Phase 2b for early Alzheimer's, while JNJ-2056 targets preclinical Alzheimer's. These designations aim to expedite development, highlighting J&J's commitment to innovative Alzheimer's treatments amidst clinical and regulatory uncertainties.
© Copyright 2025. All Rights Reserved by MedPath